TY - JOUR
T1 - Myeloid ATP Citrate Lyase Regulates Macrophage Inflammatory Responses In Vitro Without Altering Inflammatory Disease Outcomes
AU - Verberk, Sanne G S
AU - van der Zande, Hendrik J P
AU - Baardman, Jeroen
AU - de Goede, Kyra E
AU - Harber, Karl J
AU - Keuning, Eelco D
AU - Lambooij, Joost M
AU - Otto, Frank
AU - Zawistowska-Deniziak, Anna
AU - de Vries, Helga E
AU - de Winther, Menno P J
AU - Guigas, Bruno
AU - Van den Bossche, Jan
N1 - Funding Information: JVB received a VENI grant from ZonMW (91615052) and a Netherlands Heart Foundation junior postdoctoral grant (2013T003) and senior fellowship (2017T048). MW is an established investigator of the Netherlands Heart Foundation, is supported by grants from the Netherlands Heart Foundation and Spark-Holding BV (2015B002 and 2019B016), and Fondation Leducq (16CVD-01), and holds an AMC fellowship. BG received a ZonMW TOP grant from NWO, ZonMW (91214131) and HZ received a grant supported by the NWO Graduate School Program (022.006.010). Funding Information: We would like to express gratitude to Kathryn E. Wellen for providing the Aclyfl/fl mice, and to Mike de Kok, Koen H.M. Prange and Guillermo R. Griffith for their help with acquiring and analyzing transcriptomics data. Lastly, we would like to thank Priscilla Heijnen, Susanne van der Pol, Merel Rijnsburger, and Lynn van Olst for their extensive help with the animal experiments performed. Publisher Copyright: © Copyright © 2021 Verberk, van der Zande, Baardman, de Goede, Harber, Keuning, Lambooij, Otto, Zawistowska-Deniziak, de Vries, de Winther, Guigas and Van den Bossche. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4/26
Y1 - 2021/4/26
N2 - Macrophages are highly plastic, key regulators of inflammation. Deregulation of macrophage activation can lead to excessive inflammation as seen in inflammatory disorders like atherosclerosis, obesity, multiple sclerosis and sepsis. Targeting intracellular metabolism is considered as an approach to reshape deranged macrophage activation and to dampen the progression of inflammatory disorders. ATP citrate lyase (Acly) is a key metabolic enzyme and an important regulator of macrophage activation. Using a macrophage-specific Acly-deficient mouse model, we investigated the role of Acly in macrophages during acute and chronic inflammatory disorders. First, we performed RNA sequencing to demonstrate that Acly-deficient macrophages showed hyperinflammatory gene signatures in response to acute LPS stimulation in vitro. Next, we assessed endotoxin-induced peritonitis in myeloid-specific Acly-deficient mice and show that, apart from increased splenic Il6 expression, systemic and local inflammation were not affected by Acly deficiency. Also during obesity, both chronic low-grade inflammation and whole-body metabolic homeostasis remained largely unaltered in mice with Acly-deficient myeloid cells. Lastly, we show that macrophage-specific Acly deletion did not affect the severity of experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis. These results indicate that, despite increasing inflammatory responses in vitro, macrophage Acly deficiency does not worsen acute and chronic inflammatory responses in vivo. Collectively, our results indicate that caution is warranted in prospective long-term treatments of inflammatory disorders with macrophage-specific Acly inhibitors. Together with our earlier observation that myeloid Acly deletion stabilizes atherosclerotic lesions, our findings highlight that therapeutic targeting of macrophage Acly can be beneficial in some, but not all, inflammatory disorders.
AB - Macrophages are highly plastic, key regulators of inflammation. Deregulation of macrophage activation can lead to excessive inflammation as seen in inflammatory disorders like atherosclerosis, obesity, multiple sclerosis and sepsis. Targeting intracellular metabolism is considered as an approach to reshape deranged macrophage activation and to dampen the progression of inflammatory disorders. ATP citrate lyase (Acly) is a key metabolic enzyme and an important regulator of macrophage activation. Using a macrophage-specific Acly-deficient mouse model, we investigated the role of Acly in macrophages during acute and chronic inflammatory disorders. First, we performed RNA sequencing to demonstrate that Acly-deficient macrophages showed hyperinflammatory gene signatures in response to acute LPS stimulation in vitro. Next, we assessed endotoxin-induced peritonitis in myeloid-specific Acly-deficient mice and show that, apart from increased splenic Il6 expression, systemic and local inflammation were not affected by Acly deficiency. Also during obesity, both chronic low-grade inflammation and whole-body metabolic homeostasis remained largely unaltered in mice with Acly-deficient myeloid cells. Lastly, we show that macrophage-specific Acly deletion did not affect the severity of experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis. These results indicate that, despite increasing inflammatory responses in vitro, macrophage Acly deficiency does not worsen acute and chronic inflammatory responses in vivo. Collectively, our results indicate that caution is warranted in prospective long-term treatments of inflammatory disorders with macrophage-specific Acly inhibitors. Together with our earlier observation that myeloid Acly deletion stabilizes atherosclerotic lesions, our findings highlight that therapeutic targeting of macrophage Acly can be beneficial in some, but not all, inflammatory disorders.
KW - ATP citrate lyase
KW - immunometabolism
KW - inflammation
KW - macrophage
KW - obesity
KW - peritonitis
UR - http://www.scopus.com/inward/record.url?scp=85105585899&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fimmu.2021.669920
DO - https://doi.org/10.3389/fimmu.2021.669920
M3 - Article
C2 - 33981315
SN - 1664-3224
VL - 12
SP - 669920
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 669920
ER -